Figure 3. Pharmacologic blockade of iNOS improves therapeutic response of PDACs to RT.
a-c) FC1245 luciferase-expressing PDAC orthotopic tumors treated with RT, 1400W or 1400W/RT (n = 10 mice per group) and tracked by bioluminescence. Mice were treated with 3 doses of 6 Gy at 48 h intervals. Intraperitoneal administration of 1400W (1 μg g−1) was started at day 0. 1400W was administrated every day for 7 days during the RT treatment period and every two days during two weeks after the RT treatment period. Real-time images from median of two animals (b) and luminescent signal (n = 10 mice per group) on day 14 post-therapy (c). **P<0.01 compared with control and based on a Student’s t-test (a). **P<0.01, ***P<0.01 compared with RT treated group and based on a Student’s t-test. &P<0.01 compared with 1400W treated group (c).
d) H&E, cleaved caspase 3, and Ki-67 immunohistochemistry and quantification (mean ± S.E.M, n = 3) in tumors from control, RT, 1400W, and 1400W/RT groups collected on day 14 post-therapy. *P<0.05 and **P<0.01 compared with control; &P<0.05 compared with RT; $P<0.05 and $$P <0.01 compared with 1400W and based on a Student’s t-test.